NCT05687279View on ClinicalTrials.gov

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Respiratory Syncytial Virus Infection
Interventions
BIOLOGICAL

RSVt Vaccine

Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal

OTHER

Control Group

Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal

Trial Locations (6)

984

Investigational Site Number : 6300002, Carolina

68134

Velocity Clinical Research, Omaha Site Number : 8400001, Omaha

68701

Meridian Clinical Research Norfolk Site Number : 8400003, Norfolk

00960

Investigational Site Number : 6300004, Bayamón

00784

Investigational Site Number : 6300003, Guayama

00918

Investigational Site Number : 6300001, San Juan

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY